IVVD · Invivyd, Inc. · Webcasts, Transcripts & Audio
$0.82
0.00 (-0.33%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current operating plans and excluding future external financing, the Company will not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$275.36M
Shares
294.76M
Volume · Oct 5
4.25M
Avg daily vol (3M)
4.77M
Invivyd, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Invivyd, Inc. (IVVD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$
−$50.23M
'23 Q2
23-08-10
·
$
−$39.44M
'23 Q3
23-11-09
·
$
−$43.50M
'24 Q1
24-05-09
·
$2.26M
−$47.25M
'24 Q2
24-08-14
·
$9.30M
−$60.74M
'24 Q3
24-11-14
·
$13.82M
−$18.44M
'24 Q4
25-02-03
·
$11.30M
−$16.29M
'25 Q1
25-05-15
▲41.2%
$13.13M
−$10.47M
'25 Q3
25-11-06
▲24.5%
$17.21M
−$11.07M
'25 Q4
26-03-05
▲21.6%
$13.74M
−$41.40M
'26 Q1
26-05-14
LATEST
▲21.2%
$14.29M
−$44.39M
'26 Q2
26-08-13
Conference
Investor event
2026-09-14
Invivyd, Inc. (IVVD) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-13
Invivyd, Inc. (IVVD) Q2 2026 Earnings Call
Revenue
$14.29M
▲ 21.2% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Invivyd, Inc. (IVVD) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Confident tone
Public education and messaging
Monoclonal antibody platform strategy
Pivotal program recruitment and timing
Revenue
$13.74M
▲ 21.6% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-09
Invivyd, Inc. (IVVD) April 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-05
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Positive tone
VYD-2311 COVID Prophylaxis Program
Pemgarda Commercial Performance
RSV Antibody Program
Revenue
$17.21M*
▲ 24.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript
Confident tone
VYD2311 pivotal program
Discovery pipeline (RSV, nasal antibodies, measles)
PEMGARDA commercial franchise
Revenue
$13.13M
▲ 41.2% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-10-30
Invivyd, Inc. (IVVD) October 2025 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-05-15
Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript
Confident tone
SARS-CoV-2 epitope durability
Regulatory strategy and EUA-to-BLA path
PEMGARDA commercial transition and growth
Revenue
$11.30M
Diluted EPS
$-0.14
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-03
Invivyd, Inc. (IVVD) Q4 2024 Earnings Call
Revenue
$13.82M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript
Cautious tone
FDA/regulatory headwind and KP.3.1.1 susceptibility issue
Pemivibart (PEMGARDA) clinical efficacy and CANOPY data
Treatment EUA / immunobridging regulatory pathway
Revenue
$9.30M
Diluted EPS
$-0.51
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript
Positive tone
Immunocompromised patient population and unmet need
PEMGARDA commercial launch and net revenue
Pipeline molecule VYD2311
Revenue
$2.26M
Diluted EPS
$-0.40
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript
Confident tone
PEMGARDA commercial launch
Treatment opportunity and competition
Regulatory pathway and FDA alignment
Revenue
$
Diluted EPS
$-0.38
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-25
Invivyd, Inc. (IVVD) Q4 2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Invivyd, Inc. (IVVD) Q3 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.36
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Invivyd, Inc. (IVVD) Q2 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.46
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Invivyd, Inc. (IVVD) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.32
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Invivyd, Inc. (IVVD) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Invivyd, Inc. (IVVD) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.42
Audio
Transcript
Slides
8-K10-Q
Showing 1–19 of 19 webcasts